Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex H Chang

Showing results (41-50 of 71) with videos related to

Pageof 8
Sort By:
Leukemia|July 3, 2026
CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemiaMingming Zhang, Lianxuan Liu, Shan Fu, et al.
Blood Cancer Journal|April 24, 2023
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignanciesYinqiang Zhang, Chenggong Li, Mengyi Du, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2021
Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell TherapyMingming Zhang, Linghui Zhou, Houli Zhao, et al.
Bone Marrow Transplantation|August 20, 2025
Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphomaYetian Dong, Tingting Yang, Mengyu Zhao, et al.
Journal of Hematology & Oncology|April 5, 2023
Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemiaYue Tan, Lingling Shan, Liping Zhao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 27, 2026
Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001)Wenqiang Yan, Chenxing Du, Rui Lv, et al.
Molecular Therapy. Methods & Clinical Development|December 13, 2021
Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALLBiping Deng, Jing Pan, Zhaoli Liu, et al.
Blood Advances|September 14, 2021
Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphomaYing Liu, Biping Deng, Bo Hu, et al.
Frontiers in Oncology|February 19, 2021
CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin's LymphomaYuanBo Xue, Xun Lai, RuiLei Li, et al.
Journal of Hematology & Oncology|May 18, 2025
BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trialHao Yao, Shi-Hui Ren, Lin-Hui Wang, et al.
Pageof 8

Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
Leukemia|July 3, 2026
CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemiaMingming Zhang, Lianxuan Liu, Shan Fu, et al.
Blood Cancer Journal|April 24, 2023
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignanciesYinqiang Zhang, Chenggong Li, Mengyi Du, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2021
Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell TherapyMingming Zhang, Linghui Zhou, Houli Zhao, et al.
Bone Marrow Transplantation|August 20, 2025
Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphomaYetian Dong, Tingting Yang, Mengyu Zhao, et al.
Journal of Hematology & Oncology|April 5, 2023
Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemiaYue Tan, Lingling Shan, Liping Zhao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 27, 2026
Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001)Wenqiang Yan, Chenxing Du, Rui Lv, et al.
Molecular Therapy. Methods & Clinical Development|December 13, 2021
Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALLBiping Deng, Jing Pan, Zhaoli Liu, et al.
Blood Advances|September 14, 2021
Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphomaYing Liu, Biping Deng, Bo Hu, et al.
Frontiers in Oncology|February 19, 2021
CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin's LymphomaYuanBo Xue, Xun Lai, RuiLei Li, et al.
Journal of Hematology & Oncology|May 18, 2025
BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trialHao Yao, Shi-Hui Ren, Lin-Hui Wang, et al.
Pageof 8